• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Drug-coated balloon angioplasty for arteriovenous fistulas

byConstance Wu
August 26, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Drug-coated balloon angioplasty was superior to standard angioplasty for stenotic lesion treatment in hemodialysis arteriovenous fistulas.

2. Drug-coated balloon angioplasty was shown to be noninferior to standard angioplasty for adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Arteriovenous (AV) fistulas are given preference over central venous hemodialysis catheters during hemodialysis treatment. The AV fistulas provide access for renal replacement therapy while maintaining low risk for infection. However, one limitation of AV fistulas are the high incidence of vascular stenoses within the fistula circuit known as dysfunction. As such, this study investigated whether a paclitaxel-coated balloon angioplasty improved outcome in patients with dysfunctional fistulas compared to standard angioplasty. The results of the study demonstrated that the drug-coated balloon angioplasty was superior for treatment of stenotic lesions in AV fistulas compared to standard angioplasty. This randomized trial was limited by its non-blinded study design, as the drug-coated balloon had a different appearance than the standard balloon. Nonetheless, the study found a potential solution for AV fistula dysfunction to widen the adoption of this type of access.

Click to read the study in NEJM

Relevant Reading: Drug-Coated Balloon Angioplasty in Hemodialysis Circuits: A Systematic Review and Meta-Analysis

In-Depth [randomized controlled trial]: This randomized control trial enrolled 330 participants in a multicenter study at 29 sites in the Untied States, Japan, and New Zealand. Participants included in the study had a native AV fistula created at least 60 days before the procedure and used dialysis between 8 to 12 times in a four-week period. Participants with a history of access-circuit thrombosis or a previous stent in the access circuit were excluded from this study. The participants were randomized in a 1:1 ratio to receive drug-coated balloon angioplasty or standard (non-drug-coated) balloon angioplasty. The primary outcome was patency of the targeted stenotic lesion. Target-lesion patency was defined as the freedom from target-lesion revascularization or access-circuit thrombosis. During the six-month follow-up period, 82.2% (125 or 152) in the drug-coated balloon group and 59.5% (88 of 148) in the standard balloon group maintained target-lesion patency (risk difference, 22.8 percentage points; 95% confidence interval [CI], 12.8 to 32.8; P<0.001). At the end of the follow-up period, the percentage of participants with target-lesion patency was 81.4% in the drug-coated balloon group compared to 59.0% in the control group (hazard ratio, 0.39; 95% CI, 0.24 to 0.61). Additionally, there was no significant difference for the risk of access-circuit thrombosis between the two groups (drug-coated balloon group, 2.0%; standard-balloon group, 3.4%; risk difference, -1.4%; 95% CI, -5.1 to 2.3). Finally, the drug-coated balloon (4.2%) was shown to be noninferior to the standard balloon (4.4%) with respect to serious adverse events involving the AV access-circuit (risk difference, -0.2 percentage points; 95% CI, -5.5 to 5.0; P=0.002 for noninferiority). The most frequent adverse event was AV fistula site complication in both groups (drug-coated balloon group, 3.0%; standard balloon group, 2.5%). Taken together, the drug-coated balloon angioplasty was shown to be significantly superior to standard balloon angioplasty for the treatment of stenotic lesion in hemodialysis AV fistulas.

RELATED REPORTS

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Spirituality-oriented psychological counseling may reduce fear of death among hemodialysis patients

Wellness Check: Spirituality

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arteriovenous fistuladrug coated balloonhemodialysis
Previous Post

Indigenous individuals with diabetes screened less and have poorer glycemic and lipid control than the general population

Next Post

Targeted intraoperative radiotherapy associated with similar outcomes as whote breast post-operative radiotherapy for breast cancer

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Nephrology

Spirituality-oriented psychological counseling may reduce fear of death among hemodialysis patients

March 28, 2022
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women
Chronic Disease

Wellness Check: Spirituality

March 24, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Poor humoral response observed in patients undergoing hemodialysis following a single dose of the BNT162b2 SARS-CoV-2 vaccine

September 7, 2021
Next Post
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Targeted intraoperative radiotherapy associated with similar outcomes as whote breast post-operative radiotherapy for breast cancer

Pediatric palliative care outcome measures often miss quality of life

Clinical exome sequencing of stillbirths provides insight into critical genes for fetal survival

Bisphosphonate use and risk of atypical femur fractures

Bisphosphonate use and risk of atypical femur fractures

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.